The prognosis of premenopausal breast cancer patients with early disease has improved over the past decades, particularly in women expressing hormone receptors in their tumors. Tamoxifen, a selective estrogen receptor modulator, has dramatically changed outcomes in these patients and remains one of the standards of care. Ovarian function suppression by gonadotropin-releasing-hormone analogues (GnRHa) represents an additional treatment option. Long-term data are required before firm conclusions can be drawn, whereas recent clinical trials suggest that the use of GnRHa is effective in both adjuvant and metastatic settings, particularly in younger patients (<35 years old). The decision to select the optimal therapy should be individualized according to the biological characteristics of tumors, estimates of disease response, comorbidities, patient preference, and long-term toxicity.
Get full access to this article
View all access options for this article.
References
1.
SiegelRL, MillerKD, JemalA. Cancer statistics, 2015. CA Cancer J Clin, 2015; 65:5–29.
2.
AndersCK, HsuDS, BroadwaterG, et al.Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol, 2008; 26:3324–3330.
3.
CollinsLC, MarottiJD, GelberS, et al.Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat, 2012; 131:1061–1066.
4.
ParkJH, AndersonWF, GailMH. Improvements in US breast cancer survival and proportion explained by tumor size and estrogen-receptor status. J Clin Oncol, 2015; 33:2870–2876.
5.
DowsettM, FolkerdE, DoodyD, HaynesB. The biology of steroid hormones and endocrine treatment of breast cancer. Breast, 2005; 14:452–457.
6.
DavidsonNE.Ovarian ablation as treatment for young women with breast cancer. J Natl Cancer Inst Monogr, 1994; 16:95–99.
7.
AriaziEA, AriaziJL, CorderaF, JordanVC. Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem, 2006; 6:181–202.
8.
RugoHS, RumbleB, MacraeE. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American society of clinical oncology guideline. J Clin Oncol, 2016; 34:3069–3103.
9.
Early Breast Cancer Trialists' Collaborative Group, DaviesC, GodwinJ, et al.Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet, 2011; 378:771–784.
10.
CardosoF, CostaA, NortonL, et al.ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast, 2014; 23:489–502.
11.
Early Breast Cancer Trialists' Collaborative Group, DowsettM, ForbesJF, et al.Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials. Lancet, 2015; 386:1341–1352.
12.
XuHB, LiuYJ, LiL. Aromatase inhibitor versus tamoxifen in postmenopausal woman with advanced breast cancer: A literature-based meta-analysis. Clin Breast Cancer, 2011; 11:246–251.
13.
SchallyAV, Comaru-SchallyAM. Mode of action of LHRH analogs. In: KufeDW, PollockRE, WeichselbaumRR, et al., eds. Holland-Frei cancer medicine. 6th edition. Hamilton, ON: BC Decker, 2003.
14.
FurrBJ.Pharmacology of the luteinising hormone releasing hormone (LHRH) analog “Zoladex”. Horm Res, 1989; 32(Suppl 1):86–92.
15.
NCT02005887 TRial on the Endocrine Activity of Neoadjuvant Degarelix (TREND) 2013. Abstract of: DellapasquaS, ColleoniM, MaibachR. Abstract OT3-2-06 presented on Thirty-Sixth Annual CTRC-AACR San Antonio Breast Cancer Symposium - Dec10–14, 2013; San Antonio, TX, DOI 10.1158/0008-5472.
WongM, O'NeillS, WalshG, SmithIE. Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: Menstruation and pregnancy outcomes. Ann Oncol, 2013; 24:133–138.
18.
SchallyAV.Luteinizing hormone-releasing hormone analogs: Their impact on the control of tumorigenesis. Peptides, 1999; 20:1247–1262.
19.
SharoniY, BosinE, MiinsterA, LevyJ, SchallyAV. Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A, 1989; 86:1648–1651.
20.
CuzickJ, AmbroisineL, DavidsonN, et al.Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: A meta-analysis of individual patient data from randomised adjuvant trials. Lancet, 2007; 369:1711–1723.
21.
Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet, 2005; 365:1687–1717.
22.
RossiL, PaganiO. Impact of breast cancer treatment on fertility. In: BigliaN, PeccatoriFA, eds. Breast cancer, fertility preservation and reproduction. Cham, Switzerland: Springer International Publishing, 2015.
23.
HackshawA, BaumM, FornanderT, et al.Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst, 2009; 101:341–349.
24.
GoelS, SharmaR, HamiltonA, BeithJ. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev, 2009:CD004562.
25.
YanS, LiK, JiaoX, ZouH. Tamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: A meta-analysis of published randomized controlled trials. Oncol Targets Ther, 2015; 8:1433–1441.
26.
FrancisPA, ReganMM, FlemingGF. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med, 2015; 372:1673.
27.
Adjuvant Breast Cancer Trials Collaborative Group. Ovarian ablation or suppression in premenopausal early breast cancer: Results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial. J Natl Cancer Inst, 2007; 99:516–525.
28.
TevaarwerkAJ, WangM, ZhaoF, et al.Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol, 2014; 32:3948–3958.
29.
FrancisPA, ReganMM, FlemingGF, et al.Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med, 2015; 372:436–446.
30.
PaganiO, ReganMM, WalleyBA, et al.Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med, 2014; 371:107–118.
31.
GnantM, MlineritschB, StoegerH, et al.Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: Final analysis of the Austrian breast and colorectal cancer study group trial 12. Ann Oncol, 2015; 26:313–320.
32.
CoatesAS, WinerEP, GoldhirschA, et al.Tailoring therapies-improving the management of early breast cancer: St. Gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol, 2015; 26:1533–1546.
33.
Paluch-ShimonS, PaganiO, PartridgeAH, et al.Second international consensus guidelines for breast cancer in young women (BCY2). Breast, 2016; 26:87–99.
34.
BursteinHJ, LacchettiC, GriggsJJ. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline update on ovarian suppression summary. J Oncol Pract, 2016; 12:390–393.
35.
BernhardJ, LuoW, RibiK, et al.Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): A combined analysis of two phase 3 randomised trials. Lancet Oncol, 2015; 16:848–858.
36.
MasudaN, IwataH, RaiY, et al.Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat, 2011; 126:443–451.
37.
BelletM, GrayKP, FrancisPA, et al.Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): The SOFT-EST substudy. J Clin Oncol, 2016; 34:1584–1593.
38.
LeeSJ, YangEM, SeoJY, KimCJ. Effects of gonadotropin-releasing hormone agonist therapy on body mass index and height in girls with central precocious puberty. Chonnam Med J, 2012; 48:27–31.
39.
AnikA, CatliG, AbaciA, BoberE. Effect of gonadotropin-releasing hormone agonist therapy on body mass index and growth in girls with idiopathic central precocious puberty. Indian J Endocrinol Metab, 2015; 19:267–271.
40.
PfeilerG, KonigsbergR, FeslC, et al.Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the prospective ABCSG-12 trial. J Clin Oncol, 2011; 29:2653–2659.
41.
SenkusE, KyriakidesS, OhnoS, et al.Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger. Ann Oncol, 2015; 26(Suppl 5):v8–v30.
42.
LorenAW, ManguPB, BeckLN, et al.Fertility preservation for patients with cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol, 2013; 31:2500–2510.
43.
LambertiniM, CeppiM, PoggioF, et al.Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: A meta-analysis of randomized studies. Ann Oncol, 2015; 26:2408–2419.
44.
MunhozRR, PereiraAA, SasseAD, et al.Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: A systematic review and meta-analysis. JAMA Oncol, 2016; 2:65–73.
45.
PeccatoriFA, AzimHAJr., OrecchiaR, et al.Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2013; 24(Suppl 6):vi160–170.
46.
NCCN. NCCN clinical practice guidelines in oncology (NCCN Guidelines®) breast cancer version 3. Available at: www.nccn.org/professionals/physician_gls/pdf/breast.pdf Accessed October14, 2015.
47.
LambertiniM, CinquiniM, MoschettiI, et al.Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology. Eur J Cancer, 2017; 71:25–33.
48.
ProwellTM, DavidsonNE. What is the role of ovarian ablation in the management of primary and metastatic breast cancer today?. Oncologist, 2004; 9:507–517.
49.
BlameyRW, JonatW, KaufmannM, BiancoAR, NamerM. Survival data relating to the use of goserelin depot in the treatment of premenopausal advanced breast cancer. Eur J Cancer, 1993; 29A:1498.
50.
KlijnJG, BlameyRW, BoccardoF, et al.Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. J Clin Oncol, 2001; 19:343–353.
51.
MichaudLB, JonesKL, BuzdarAU. Combination endocrine therapy in the management of breast cancer. Oncologist, 2001; 6:538–546.
52.
NishimuraR, AnanK, YamamotoY, et al.Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: Results of the JMTO BC08-01 phase II trial. Oncol Rep, 2013; 29:1707–1713.
53.
TorrisiR, BagnardiV, PruneriG, et al.Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. Br J Cancer, 2007; 97:802–808.
54.
CarlsonRW, TheriaultR, SchurmanCM, et al.Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol, 2010; 28:3917–3921.
55.
ForwardDP, CheungKL, JacksonL, RobertsonJF. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer, 2004; 90:590–594.
56.
LiuX, QuH, CaoW, et al.Efficacy of combined therapy of goserelin and letrozole on very young women with advanced breast cancer as first-line endocrine therapy. Endocr J, 2013; 60:819–828.
57.
RobertsonJF, SemiglazovV, NemsadzeG, et al.Effects of fulvestrant 250 mg in premenopausal women with oestrogen receptor-positive primary breast cancer. Eur J Cancer, 2007; 43:64–70.
58.
BartschR, Bago-HorvathZ, BerghoffA, et al.Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. Eur J Cancer, 2012; 48:1932–1938.
59.
TurnerNC, Huang BartlettC, CristofanilliM. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med, 2015; 373:1672–1673.
60.
ImS, ChowL, ShaoZ, et al.Study of efficacy and safety in premenopausal women with hormone receptor positive, HER2-negative advanced breast cancer (MONALEESA-7) 2014. NCT02278120. Annals of Oncology, 2015; 26:16–33.
61.
SousaB, MoserE, CardosoF. An update on male breast cancer and future directions for research and treatment. Eur J Pharmacol, 2013; 717:71–83.
62.
GiordanoSH, CohenDS, BuzdarAU, PerkinsG, HortobagyiGN. Breast carcinoma in men: A population-based study. Cancer, 2004; 101:51–57.
63.
EggemannH, IgnatovA, SmithBJ, et al.Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat, 2013; 137:465–470.
64.
ZagouriF, SergentanisTN, AzimHAJr., ChrysikosD, DimopoulosMA, PsaltopoulouT.Aromatase inhibitors in male breast cancer: A pooled analysis. Breast Cancer Res Treat, 2015; 151:141–147.
65.
Di LauroL, PizzutiL, BarbaM, et al.Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: Results from a pooled analysis. J Hematol Oncol, 2015; 8:53.
66.
MasudaN, SagaraY, KinoshitaT, et al.Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): A double-blind, randomised phase 3 trial. Lancet Oncol, 2012; 13:345–352.
67.
PartridgeAH, PaganiO, AbulkhairO, et al.First international consensus guidelines for breast cancer in young women (BCY1). Breast, 2014; 23:209–220.
